Jun 15, 2020
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
Mar 31, 2020
New Retrospective Two-Year Study Demonstrates Velphoro® Effectiveness
Dec 03, 2019
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
Sep 03, 2019
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Jun 25, 2019
US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia's Auryxia, Amgen's Parsabiv, and Opko's Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products
Mar 07, 2019
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Feb 07, 2019
Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Jan 28, 2019
Velphoro® Doubles Percentage of Patients Reaching Target Serum Phosphorous Levels in New Study Published in Journal of Renal Nutrition
Nov 07, 2018
Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
Oct 26, 2018
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Mar 19, 2018
Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
Nov 14, 2017
In the CKD-MBD Market, OPKO's Rayaldee Continues to Struggle While Keryx's Auryxia Gains Momentum, According to Latest Quarterly Update from Spherix Global Insights
Aug 10, 2017
Changes Afoot in the Management of CKD Mineral Bone Disorder Reinforced by a Clinical Practice Guideline Update from KDIGO